Ozenoxacin, a novel non-fluorinated topical quinolone, was assessed for in vitro antimicrobial activity against clinical isolates of propionibacteria and staphylococci according to the broth microdilution method recommended by the Clinical and Laboratory Standards Institute. The isolates used in this study were collected from Japanese patients with acne vulgaris during a period from 2012 to 2013. The MIC 90 s of ozenoxacin against Propionibacterium acnes (n=266), Propionibacterium granulosum (n=10), Staphylococcus aureus (n=23), Staphylococcus epidermidis (n=229) and other coagulase-negative staphylococci (n=82) were 0.06, 0.06, 0.06, 0.125 and 0.06 µg ml À1 , respectively. The antimicrobial activity of ozenoxacin against the clinical isolates of propionibacteria and staphylococci was greater than that of five reference antimicrobial agents which have been used for the treatment of acne vulgaris. The MICs of ozenoxacin were correlated with those of nadifloxacin in P. acnes and S. epidermidis isolates. However, the MICs of ozenoxacin were 0.25-0.5 µg ml À1 and 0.5-8 µg ml À1 against nadifloxacin-resistant P. acnes (MIC: !8 µg ml À1 ; n=8) and S. epidermidis (MIC: !64 µg ml À1 ; n=10), respectively. These results indicated the potent antimicrobial activity against P. acnes and S. epidermidis isolates resistant to nadifloxacin. Topical ozenoxacin could represent an alternative therapeutic drug for acne vulgaris based on its potent antimicrobial activity against the isolates of propionibacteria and staphylococci from acne patients.
INTRODUCTION
Acne vulgaris is the most common skin disease worldwide, frequently affecting adolescents and often persisting or occurring in adulthood (Williams et al., 2012) . The clinical picture is manifested by seborrhoea, non-inflammatory comedones (blackheads and whiteheads), inflammatory papules, pustules or nodules and scarring, which originate from the pilosebaceous units (Strauss et al., 2007; Thiboutot et al., 2009; Nast et al., 2012) . The pathogenesis of acne is multifactorial and includes increased sebum production by androgen-mediated hyperactive sebaceous gland, follicular hyperkeratinization, bacterial colonization by Propionibacterium acnes, a common anaerobic Grampositive commensal of normal skin and release of inflammatory mediators (Contassot et al., 2014; Beylot et al., 2014) . Multiple acne therapies are available depending on the severity, type and extent of acne lesions and topical retinoids, antimicrobials and benzoyl peroxide, oral antimicrobials and oral isotretinoin (retinoid) (Strauss et al., 2007; Thiboutot et al., 2009; Nast et al., 2012) . In addition, both topical and oral antimicrobials are recommended to be combined with topical retinoids or benzoyl peroxide, or to limit the duration of use in monotherapy in order to minimize the incidence of bacterial resistance, which has become an increasing concern in the management of acne (Patel et al., 2010; Nakase et al., 2014) .
Ozenoxacin is a novel des-fluoro-(6)-quinolone antimicrobial agent developed for topical use (Yamakawa et al., 2002; López et al., 2013) . In Japan, 2 % ozenoxacin-containing lotion (Zebiax® Lotion 2 %; Maruho, Osaka, Japan) has recently been approved as an ethical pharmaceutical agent for acne vulgaris and superficial skin infections such as folliculitis, sycosis, periporitis suppurativa and impetigo (Kawashima et al., 2015a, b) . Ozenoxacin has a broad antimicrobial spectrum against both Grampositive and Gram-negative organisms, including major pathogenic bacteria of acne vulgaris and superficial skin infections such as P. acnes, Staphylococcus aureus and Staphylococcus epidermidis (Yamakawa et al., 2002; López et al., 2013 López et al., , 2015 Tato et al., 2014) . Moreover, ozenoxacin was the most potent against all organisms compared to any reference antimicrobial agents tested (Yamakawa et al., 2002; López et al., 2013 López et al., , 2015 Tato et al., 2014) . However, to date there are no data concerning the in vitro antimicrobial activity of ozenoxacin against bacteria isolated from patients with acne vulgaris.
In the present study, therefore, the in vitro antimicrobial activity of ozenoxacin was examined against isolates of propionibacteria and staphylococci from Japanese patients with acne vulgaris and compared to those of existing antimicrobial agents for the treatment of acne vulgaris in Japan.
METHODS
Clinical isolates. A total of 649 clinical isolates collected during a period from 2012 to 2013 were used in this study. The clinical isolates originated from pustule specimens of Japanese patients with acne vulgaris. They included P. acnes (n=266), Propionibacterium granulosum (n=10), S. aureus (n=23), S. epidermidis (n=229) and other coagulase-negative staphylococci (CNS) (n=82). All clinical isolates were used according to the Japanese Ethical Guidelines for Epidemiological Research, and patient information was unlikeably anonymized.
Antimicrobial agents. Ozenoxacin was obtained from Toyama Chemical (Tokyo, Japan). Nadifloxacin was purchased from LKT Laboratories (Saint paul, MN, US). Clindamycin, erythromycin, gentamicin and minocycline were purchased from Eiken Chemical (Tokyo, Japan) as twofold serially diluted and freeze-dried 96-well microplates.
MIC assay. All antimicrobial agents were diluted by cation-adjusted Muller-Hinton broth (Eiken Chemical) for staphylococci and by anaerobic bacterial culture medium (Eiken Chemical) for propionibacteria in a twofold serial manner. The final concentrations of ozenoxacin ranged from 0.06 to 16 µg ml
À1
. The final concentrations of other antimicrobial agents ranged from 0.06 to 128 µg ml
. MICs were determined by the broth microdilution method according to the Clinical and Laboratory Standards Institute (CLSI) (CLSI, 2012a) . The MICs of the antimicrobial agents against the quality control strains (Bacteroides fragilis ATCC25285 for propionibacteria and S. aureus ATCC29213 for staphylococci) were confirmed as meeting the criteria defined by CLSI standard methods (CLSI, 2008 (CLSI, , 2012a or the internal criteria validated for ozenoxacin and nadifloxacin. The MIC was regarded as 0.06 µg ml À1 when no growth was observed in the wells containing 0.06 µg ml À1 of each drug. 
RESULTS
Antimicrobial susceptibility Table 1 shows the MICs of ozenoxacin3 and other antimicrobial agents against clinical isolates of P. acnes, P. granulosum, S. aureus, S. epidermidis and other CNS. The MIC 90 of ozenoxacin against the isolates of both P. acnes and P. granulosum was 0.06 µg ml
À1
. The MIC 90 s of ozenoxacin against the isolates of S. aureus, S. epidermidis and other CNS were 0.06, 0.125 and 0.06 µg ml À1 , respectively. The MIC 90 of ozenoxacin was equal to or lower than that of other antimicrobial agents against the isolates of propionibacteria and staphylococci from acne vulgaris patients. MIC correlation between ozenoxacin and other antimicrobial agents (Figs 1a and 2a) . However, the MICs of ozenoxacin against eight nadifloxacin-resistant P. acnes isolates (MIC: !8 µg ml (Figs 1b and 2b) . The MICs of ozenoxacin against eight isolates of clindamycin-highly resistant P. acnes (MIC: >128 µg ml
) ranged from 0.06 to 0.5 µg ml
. Against 78 isolates of clindamycin-highly resistant S. epidermidis (MIC: >128 µg ml À1 ), the MICs of ozenoxacin ranged from 0.06 to 8 µg ml À1 .
DISCUSSION
Propionibacteria and staphylococci, which are normal flora of the skin, are more frequently isolated from inflammatory sites of patients with acne vulgaris (Iinuma et al., 2009) . Especially, P. acnes is regarded as a causative bacterium involved in the pathogenesis and exacerbation of acne vulgaris (Gollnick et al., 2003; Beylot et al., 2014) . Moreover, it has been reported that P. acnes was simultaneously isolated with staphylococci in severe acne patients (Nishijima et al., 2000) . Therefore, co-localization of these bacteria is considered to contribute to the exacerbation of inflammation of acne. Topical and oral antimicrobial agents have been used for the treatment of inflammatory lesions of acne vulgaris (Strauss et al., 2007; Thiboutot et al., 2009; Nast et al., 2012) . Moreover, in acne therapy using antimicrobial agents it is recommended to be combined with topical retinoids or benzoyl peroxide or to limit the duration of use because of the risk of bacterial resistance.
The present study indicated that in vitro antimicrobial activities of ozenoxacin against the clinical isolates of propionibacteria and staphylococci are more potent than those of the existing antimicrobial agents including nadifloxacin, clindamycin, erythromycin, gentamicin and minocycline available for treatment of acne vulgaris and superficial skin infections in Japan as well as the USA and Europe. Moreover, ozenoxacin showed potent antimicrobial activity against P. acnes and S. epidermidis isolates which were lowsusceptible or resistant to nadifloxacin or clindamycin. These findings are in agreement with previous reports indicating that the antimicrobial activity of ozenoxacin is more potent than that of the existing quinolone antimicrobial agents, including nadifloxacin, against clinical isolates of P. acnes and Staphylococcus spp. (Yakamawa et al., 2002; López et al., 2013 López et al., , 2015 . In our study, we selected nadifloxacin as a reference quinolone because it has been widely used for topical application of acne vulgaris in Japan. Furthermore, it was previously reported that the MIC 90 s of nadifloxacin against P. acnes and S. epidermidis isolated from acne patients were comparable to those of levofloxacin as a standard reference drug for the study about phenotypic fluoroquinolone resistance (Nakase et al., 2014) . Therefore, we considered that the MICs of nadifloxacin are available whether or not the organisms are fluoroquinolone resistant. Consequently, the results of Figs 1(a) and 2(a) suggest that ozenoxacin showed potent antibacterial activity against fluoroquinolone-resistant isolates of P. acnes and S. epidermidis.
The potent antimicrobial activity of ozenoxacin is probably due to the greater inhibitory effect of the agent on both DNA gyrase and topoisomerase IV of these bacteria. Mutations in DNA gyrase and/or DNA topoisomerase are well known as major mechanisms of quinolone resistance. It has been reported that quinolone resistance of S. aureus was mainly caused by amino acid substitution in the quinolone resistancedetermining region of gyrA and grlA genes encoding DNA gyrase and topoisomerase IV, respectively (Ferrero et al., 1995; Horii et al., 2007) . In fact, the MICs of quinolones tended to rise depending on the number of amino acid substitution in clinical isolates of MRSA (Horii et al., 2007) . Nevertheless, ozenoxacin showed potent antimicrobial activity even against quinolone-resistant S. aureus with single to quadruple mutations in the gyrA and grlA genes (Yakamawa et al., 2002; López et al., 2013) . However, those resistant mechanisms have not been reported in P. acnes. Further studies will be necessary to elucidate possible factors underlying the quinolone resistance in P. acnes.
Recent clinical study has demonstrated the efficacy and safety of topical 2 % ozenoxacin-containing lotion in Japanese patients with acne vulgaris (Kawashima et al., 2015) . The therapeutic effect of topical ozenoxacin on acne vulgaris is probably explained by our present findings of the potent antimicrobial activity of the drug against the isolates of propionibacteria and staphylococci from acne patients. Topical ozenoxacin could represent an alternative therapeutic drug for acne vulgaris.
